Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822246 | PMC |
http://dx.doi.org/10.25646/5985 | DOI Listing |
J Clin Endocrinol Metab
January 2025
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of San Francisco, CA.
Indian J Endocrinol Metab
December 2024
Department of Endocrinology, Centre for Diabetes, Endocrinology and Metabolism, University College of Medical Sciences and GTB Hospital, Delhi, India.
Cardiovasc Diabetol
January 2025
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of GLP-1 to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential.
View Article and Find Full Text PDFGastroenterol Clin North Am
March 2025
Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, 420 Delaware Street SE, MMC 36, Minneapolis, MN 55455, USA. Electronic address:
Arq Bras Oftalmol
January 2025
Ophthalmology Department, Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!